Gemma L. Shireby

The paper develops a multivariate methylation risk score using blood DNA methylation data to predict dementia risk and cognitive impairment in Alzheimer's and Parkinson's disease cohorts.

The paper investigates epigenetic age acceleration in white matter of MSA and control brains, finding that oligodendrocyte proportions influence age acceleration.

The paper identifies DNA methylation signatures in Alzheimer's disease cortex, showing most changes are driven by non-neuronal cell types.

This paper introduces and validates a metric to assess the accuracy of cellular deconvolution in DNA methylation studies, showing it identifies biases in different demographic groups.

This study compares Nanopore sequencing with DNA methylation microarrays to evaluate its viability for epigenetic epidemiology, finding high correlation and significant smoking-associated methylation sites.

This study compares DNA methylation signatures of ageing and inflammation in blood and brain tissues, finding divergent correlations and a link between epigenetic age acceleration and microglial burdens in the hippocampus.

The paper develops a novel epigenetic clock for fetal brain development to predict prenatal age in iPSCs and derived neurons, showing they remain epigenetically fetal despite differentiation.

This study performs a meta-analysis of DNA methylation data from Alzheimer's disease patients to identify differentially methylated loci across brain regions and cortex.

The paper develops a novel DNA methylation clock optimized for human cortex tissue, outperforming existing clocks and highlighting issues with previous associations between DNA methylation age and neurodegenerative phenotypes.